1
|
Wang XK, Zhou FF, Tao HR, Wang X, Zhang C, Su F, Wang SP, Xu LH, Pan XK, Feng MH, Xie W. Knockdown of GRHL3 inhibits activities and induces cell cycle arrest and apoptosis of human colorectal cancer cells. Curr Med Sci 2017; 37:880-885. [PMID: 29270747 DOI: 10.1007/s11596-017-1821-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Revised: 11/01/2017] [Indexed: 12/14/2022]
Abstract
The Grainyhead-like 3 (GRHL3) is involved in epidermal barrier formation, neural tube closure and wound repair. Previous studies have suggested that GRHL3 has been linked to many different types of cancers. However, to date, its effects on human colorectal cancer (CRC) has not been clarified yet. Our microarray analysis has indicated predominant GRHL3 expression in CRC. The purpose of this study was to investigate the expression and significance of GRHL3 in CRC tumorigenesis using CRC tissues and paired paracancerous tissues, as well as using distinct CRC cell lines (HT29 and DLD1). We observed increased GRHL3 expression at both mRNA and protein levels in CRC tissues and CRC cell lines using quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting. Moreover, silencing GRHL3 with siRNA could suppress CRC cell proliferation, viability and migration in vitro. We also found that knockdown of GRHL3 could promote cell cycle arrest at G0/G1 phase in HT29 cells and DLD1 cells, and induce cell apoptosis in HT29 cells. Together, our study revealed the down-regulation of GRHL3 in vitro could inhibit CRC cell activity and trigger cell cycle arrest at G0/G1 phase and apoptosis.
Collapse
Affiliation(s)
- Xiao-Kang Wang
- Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
| | - Fen-Fang Zhou
- Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
| | - Hao-Ran Tao
- School of Clinical Medicine, Fenyang Medical College, Shanxi Medical University, Fenyang, 032200, China
| | - Xin Wang
- Department of General Surgery, Tongshan Renmin Hospital, Tongshan, 437400, China
| | - Chi Zhang
- Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
| | - Fei Su
- Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
| | - Shi-Pei Wang
- Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
| | - Li-Hua Xu
- Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
| | - Xue-Kai Pan
- Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
| | - Mao-Hui Feng
- Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
| | - Wei Xie
- Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
| |
Collapse
|